glp 1 medication otc U.S. Obesity Rate Drops As GLP-1 Usage Grows and stomach upset Scam weight-loss drops marketed to

Key Takeaways Prescribers and pharmacies will submit prior authorization requests and claims to a CMS contractor, not Part D plans or their PBMs Detailed conditions for beneficiary eligibility specified Patients will have a copay of $50, but pharmacy reimbursement details remain to be specified Background on the BALANCE Model CMS announced the BALANCE Model in December of last year, in which CMS will negotiate directly with manufacturers on behalf of Part D plan sponsors and state Medicaid agencies for more favorable costs and terms for GLP-1 medications

Kidney Int Rep 9:214224

D-allulose has been assessed by EFSA as safe at specified uses and levels, though UK authorisation conditions apply

However, scientific evidence is mixed, and more comprehensive research is needed